Research Paper Volume 11, Issue 6 pp 1716—1732

Elevated FPR confers to radiochemoresistance and predicts clinical efficacy and outcome of metastatic colorectal cancer patients

Figure 2. Comparison and evaluation of FPR, AFR and survival between right- and left-sided mCRC patient in two cohorts. (a) FPR in discovery cohort; (b) AFR in discovery cohort; (c) Kaplan-Meier curve of primary tumor sidedness for PFS; (d) Kaplan-Meier curve of primary tumor sidedness for OS; (e) Kaplan-Meier curve of FPR for PFS of left-sided mCRC patient in discovery cohort; (f) Kaplan-Meier curve of FPR for OS of left-sided mCRC patient in discovery cohort; (g) Kaplan-Meier curve of FPR for PFS of left-sided mCRC patient in validation cohort; (h) Kaplan-Meier curve of FPR for OS of left-sided mCRC patient in validation cohort; (i) Time-dependent ROC analysis for PFS of left-sided mCRC patient in discovery cohort; (j) Time-dependent ROC analysis for OS of left-sided mCRC patient in discovery cohort; (k) Time-dependent ROC analysis for PFS in validation cohort; (l) Time-dependent ROC analysis for OS in validation cohort.